Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Kramer

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Journal of Child Neurology|January 24, 2016
Rare Primary Central Nervous System Tumors Encountered in PediatricsKim Kramer
Pediatric Blood & Cancer|April 30, 2014
Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignanciesKim Kramer, Mariel Smith, Mark M Souweidane
Cancer Immunology, Immunotherapy : CII|February 3, 2021
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapyKim Kramer, Maria A Donzelli, Melissa S Pessin
Journal of Pediatric Hematology/Oncology|August 7, 2003
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysisKim Kramer, Brian H Kushner, Nai-Kong V Cheung
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 2, 2020
Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular RadioimmunotherapyKim Kramer, Maria Donzelli, Emmanuela Nwora, et al.
Cancer|September 7, 2002
Chronic neuroblastomaBrian H Kushner, Kim Kramer, Nai-Kong V Cheung
Journal of Neurosurgery. Pediatrics|March 3, 2012
Establishing successful cerebrospinal fluid flow for radioimmunotherapyKim Kramer, Heather J McCrea, Cheryl Fischer, et al.
Pediatric Blood & Cancer|November 5, 2010
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecanBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I studyBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Journal of Child Neurology|January 24, 2016
Rare Primary Central Nervous System Tumors Encountered in PediatricsKim Kramer
Pediatric Blood & Cancer|April 30, 2014
Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignanciesKim Kramer, Mariel Smith, Mark M Souweidane
Cancer Immunology, Immunotherapy : CII|February 3, 2021
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapyKim Kramer, Maria A Donzelli, Melissa S Pessin
Journal of Pediatric Hematology/Oncology|August 7, 2003
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysisKim Kramer, Brian H Kushner, Nai-Kong V Cheung
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 2, 2020
Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular RadioimmunotherapyKim Kramer, Maria Donzelli, Emmanuela Nwora, et al.
Cancer|September 7, 2002
Chronic neuroblastomaBrian H Kushner, Kim Kramer, Nai-Kong V Cheung
Journal of Neurosurgery. Pediatrics|March 3, 2012
Establishing successful cerebrospinal fluid flow for radioimmunotherapyKim Kramer, Heather J McCrea, Cheryl Fischer, et al.
Pediatric Blood & Cancer|November 5, 2010
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecanBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I studyBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
Pageof 11